Germany-based Medac GmbH entered an agreement with Enzon Inc.to market Oncaspar, a drug for acute lymphoblastic leukemia, inEurope and Russia.
Financial terms were not disclosed. Enzon, of Piscataway, N.J., willsell Oncaspar to Medac, of Hamburg, Germany, at a predeterminedprice that will escalate over the course of their alliance.
Oncaspar combines the L-asparaginase enzyme with polyethyleneglycol (PEG) for treatment in patients who develop hypersensitivityto native asparaginase, which is an approved cancer therapy. ThePEG-L asparaginase is designed to disguise the enzyme to prevent animmune system reaction to it.
Oncaspar is approved in Russia and Germany. In its agreement withEnzon, Medac will be responsible for seeking marketing clearance inother European countries and for conducting clinical trials to expandthe label for use in other diseases, such as non-Hodgkin's lymphoma,chronic lymphocytic leukemia and AIDS related lymphoma.
Oncaspar was approved in the U.S. in 1994 and is marketed byRhone-Poulenc Rorer Inc., of Collegeville, Pa., for acutelymphoblastic leukemia. Rorer also is conducting clinical trials toexpand use of the drug.
Enzon has a second drug approved in the U.S. Adgen, PEG-adenosine deaminase, is sold by Enzon for treatment of severecombined immunodeficiency disease.
Enzon's stock (NASDAQ:ENZN) closed Tuesday unchanged at$2.75. _ Charles Craig
(c) 1997 American Health Consultants. All rights reserved.